Now, individuals can get valuable Cancer Treatment Centers of America information by going online to WebMD. This cancer treatment giant has determined that more accessible and accurate cancer facts and treatment related information can drastically lower the high mortality rate that cancer holds. It is believed that many patients die from cancer because they did not recognize classic cancer signs until it was too late for appropriate treatments to work. By pairing with WebMD, CTCA is offering a whole new group of individuals highly accurate and currently relevant cancer treatment, symptoms and supportive therapy details. As more people become educated regarding cancer, those high mortality statistics start to decline in numbers.
Cancer Treatment Centers of America is a top cancer specialist organization that has provided superb cancer care for many years and decades. Many people are eternally grateful to CTCA for their compassionate and cutting edge cancer care for either themselves or their close family members and friends that have cancer. WebMD now is taking the highly complex health information on cancer and is translating the details into easy-to-read and digest articles. As this information is known to be some of the latest research, drugs and treatment in the oncology field today, online readers are ensured of accurate and cutting edge cancer information, statistics and facts.
When someone gets a diagnosis of some form of cancer, the immediate reaction is typically one of unbelief. As they begin to understand the cancer diagnosis implications, many patients become very scared and confused on what is to come next. Cancer Treatment Centers of America staff members have always given their valuable patients informative and truthful cancer information throughout their cancer treatments. This cancer education process continues for the whole course of each patient’s very unique case. The educational materials are highly patient personalized. Click here
Cancer Treatment Centers of America (CTCA) operates in five hospitals in the US. It runs in Atlanta, Phoenix, Chicago, Tulsa, and Philadelphia. CTCA has consistently been rated as one of the best centers in the US that offer high-quality care and patient experience. The center has partnered with other players in the healthcare industry to provide a personalized technical recommendation. The other partners of CTCA are Allscripts and NantHealth. Eviti is a NantHealth clinical decision care solution. The three healthcare providers partnered to form the Clinical Pathways program, which helps to inform on the cancer treatment process without causing disruptions to the clinical workflow of patients.
The Clinical Pathways offers real-time functionality, access to referenced response rates, toxicity, and adverse drug reactions, supporting clinical data, and comparisons between cancer treatment options. Eviti will be integrated with Allscripts Sunrise HER for the platform to enable physicians to retrieve information from an impartial Evidence-Based Medical Library. The library has more than 2,700 of the best evidence-based treatment regimens detailing all types of cancers, all modalities, and cancer subtypes. The library is compiled from oncology associations, clinical informatics experts, oncology nurses, advisory board oncology experts, and peer-reviewed literature. Health providers can present directly into order entry via open technique ability offered by Allscripts after a regimen is selected.
About Cancer Treatment Centers of America
It is a center that specializes in treating cancer patients and disseminating information to their families. CTCA uses in integrative treatment model to treat cancer using conventional methods such as chemotherapy, surgery, and immunotherapy. It also provides patients with evidence-informed supportive rehabilitations to manage side effects of cancer. CTCA operates in five hospitals in the US, which are situated in major metropolitan areas. All the centers have cancer professionals who use advanced treatments and leading-edge technology to offer specialized care.
To Learn More Click Here
Clay B. Siegall is a Ph.D. holder and a time-proven scientist. His involvement revolves around research, where he focuses on cancer therapies. Clay earned his B.S in Zoology from the University of Maryland and again pursued his Ph.D. from George Washington University. He is committed to finding a lasting solution for the cancer patients and their loved ones. His career life begun taking shape when he worked with National Cancer Institute, National Institutes of Health, between 1988 and 1991. Again in 1991, he started working with the Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Dr. Siegall appreciates the invaluable skills he gained in those institutions that he served before co-founding Seattle Genetics.
General Information About Seattle Genetics
Siegall co-founded Seattle in 1998, and he serves there as the president, CEO and board chairman. The primary reason for the inception was to enhance cancer therapies. There was a great motivation that came from Clay’s father’s illness. Siegall’s father was diagnosed with cancer when he was 19. He suffered from the life-threatening disease for five years, and Clay was watching. Mr. Clay Siegall got motivated to pursue cancer treatment so as to deliver the patients from the agony. The company has registered great milestones so far. They have succeeded in creating drugs that are FDA approved, the major one being in 2011, where their first ADC products were approved.
Various Administrative Positions Held by Clay Siegall
Mr. Clay served at Onyx Pharmaceuticals, Inc. as the Vice President and Chief Financial Officer. As well, he served as an independent director for Ultragenyx. The pharmaceuticals firm took him in because they believed in his proven proficiency in the biopharmaceutical industry. When joining the company, Clay appreciated the significant progress they had made in their clinical programs. Being a supporter of development, he pledged his allegiance in working with Ultragenyx in achieving greater goals ahead of them.
Clay’s Appointment at Mirna Therapeutics Inc.
In January 2013, Clay experienced a boost in his career when he got appointed to the board of directors at Mirna Therapeutics Inc. The firm mainly focuses on creation and commercialization of microRNA (miRNA) therapeutics. Being an exciting environment for cancer research, it got him serving in his most relevant area of specialty.